ULTIMOVACS ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.58 NOK | -3.56% |
|
-24.95% | -93.83% |
| Apr. 17 | Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments | MT |
| Apr. 17 | Transcript : Ultimovacs ASA - Special Call |
| Sales 2024 * | 954M 86.9M | Sales 2025 * | - | Capitalization | 261M 23.77M |
|---|---|---|---|---|---|
| Net income 2024 * | 654M 59.6M | Net income 2025 * | -140M -12.76M | EV / Sales 2024 * | -0.96 x |
| Net cash position 2024 * | 1.18B 107M | Net cash position 2025 * | 1.05B 95.65M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
0.46
x | P/E ratio 2025 * |
-1.98
x | Employees | 26 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ultimovacs ASA
More recommendations
More press releases
| 1 day | -3.56% | ||
| 1 week | -24.95% | ||
| Current month | -4.89% | ||
| 1 month | -2.82% | ||
| 3 months | -94.51% | ||
| 6 months | -93.23% | ||
| Current year | -93.83% |
1 week
7.48
8.90
1 month
7.4813.70
Current year
6.07165.00
1 year
6.07178.60
3 years
6.07178.60
5 years
6.07178.60
10 years
6.07178.60
| Managers | Title | Age | Since |
|---|---|---|---|
Carlos de Sousa
CEO | Chief Executive Officer | 66 | 20-05-31 |
| Director of Finance/CFO | 57 | - | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jónas Einarsson
CHM | Chairman | 67 | 11-01-25 |
Henrik Schüssler
BRD | Director/Board Member | 61 | 14-12-31 |
Kari Grønås
BRD | Director/Board Member | 59 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 7.58 | -3.56% | 496,380 |
| 24-04-23 | 7.86 | -0.51% | 287,821 |
| 24-04-22 | 7.9 | -4.93% | 261,462 |
| 24-04-19 | 8.31 | -0.60% | 574,668 |
| 24-04-18 | 8.36 | -4.46% | 897,326 |
Real-time Oslo Bors, April 24, 2024 at 10:45 am EDT
More quotes
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
7.58
NOK
Average target price
6.5
NOK
Spread / Average Target
-14.25%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -93.83% | 24.74M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- ULTI Stock
